Humana shares jump 48% in a month on Medicare Advantage growth and strong Q1 results

Humana's stock has surged 48% over the past month, outperforming peers like UnitedHealth and Cigna, driven by strong Medicare Advantage (MA) growth and favorable regulatory decisions. The company reported Q1 2026 adjusted EPS of $10.31, beating estimates, with revenue up 24% year-over-year, and affirmed full-year guidance. While the stock is consolidating near $300 after a recent breakout, future gains depend on execution and upcoming Medicare Advantage enrollment and Star Ratings updates. Despite the rally, some analysts caution the stock may be overvalued, and the recent gains reflect a recovery from past declines rather than a new bull market.